About Event
The Definitive Industry-Lead Cell Engager Summit
The 7th T-Cell Engager Therapeutics Summit is the definitive global gathering dedicated to accelerating the clinical and commercial success of T-cell engagers. As the field continues its rapid evolution, this year’s event will dive deeper than ever into groundbreaking advancements shaping the next generation of therapies.
From novel target discovery to advanced engineering strategies, the summit will spotlight the most promising innovations transforming TCE development. Discussions will unravel how researchers are expanding beyond CD3-based approaches, integrating multispecific formats, and refining affinity tuning to enhance selectivity and therapeutic potency. Experts will also explore the critical challenge of durability—how CD2 costimulation and precision dosing strategies are unlocking prolonged responses while mitigating toxicity risks.
Beyond oncology, the Summit will highlight the expanding role of TCEs in autoimmune diseases, where researchers are fine-tuning immune modulation to create more precise, targeted therapies. With an increasing focus on conditional activation, dual- and trispecific engagers, and alternative immune cell modalities, the field is entering an exciting new era.
Bringing together trailblazing biotechs, leading pharma, and top-tier research institutions, this is the must-attend event to gain cutting-edge insights, forge new collaborations, and drive the future of immune cell engager therapies forward.
Join Your Peers to:
Tarlatamab’s Clinical Evolution & Combination Strategies
Analyze tarlatamab’s efficacy, resistance, and safety in trials, and explore Amgen’s combination approaches to enhance T cell engager therapies
HLA-Targeted Engagers for Precision Tumor Targeting
Assess Clasp Therapeutics’ novel HLA-directed engagers to improve tumor infiltration and enhance T cell specificity
MAIT Cells to Expand T Cell Engager Therapeutic Index
Explore MAIT cell modulation with Biomunex to reduce CRS, mitigate toxicity, and optimize T cell redirection strategies
T Cell Engagers in Autoimmune Disease: Mechanistic Insights Compare autoimmune-focused T cell engager designs and discuss Cullinan Therapeutics’ latest clinical advancements
Co-Stimulatory Strategies to Overcome T Cell Exhaustion
Investigate Rondo Therapeutics and Merck’s approaches to enhance T cell activation while limiting cytokine release
Who Will You Meet?
Bringing together 80+ experts in T cell engagers and related modalities, this forum unites CxOs, VPs, and Directors from pioneering biotechs and major pharma. Attendees will include leaders in oncology and immunology, alongside specialists advancing macrophage and dendritic cell engagers, fostering collaboration at the forefront of immune cell redirection therapies.
What Your Peers Have to Say
“Quality presentations” – Scientist, Janssen
“Outstanding value, great speakers provided excellent content on very hot space!” - Co-Founder & Chief Executive Officer, Link Immunotherapeutics